Together, Standing Up to Ovarian Cancer is an informational program hosted and organized by your institution.
Below, you can download tools to help educate patients and caregivers about ovarian cancer, genetic testing, and much more.
Click to download tools to help create informed and meaningful dialogues with your audiences:
Lead your discussion about ovarian cancer and family risk, including how genetic testing can play an important role in determining family risk and treatment selection26,27
Customizable Presentation Flyer
Encourage patient and caregiver attendance through flyers that combine your personalized information with details of the program
Patient Leave Behind
Provide patients and caregivers with key information in a summary of the presentation that can be printed to take home
An overview of each asset in the Together, Standing Up to Ovarian Cancer program to demonstrate how your institution can successfully facilitate every event
1. Fearon ER. Human cancer syndromes: clues to the origin and nature of cancer. Science. 1997;278(5340):1043–1105. 2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2015. 3. Ferla R, Calò V, Cascio S, et al. Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol. 2007;18(suppl 6):vi93-vi98. 4. Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2654-2663. Erratum in: J Clin Oncol. 2012 Nov 20;30(33):4180. 5. Lakhani SR, Manek S, Penault-Llorca F, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res. 2004;10(7):2473-2481. 6. National Cancer Institute. BRCA1 and BRCA2: Cancer risk and genetic testing. Fact sheet. http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA. 7. Hall MJ, Reid JE, Burbidge LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115(10):2222-2233. 8. Vargas CA, Da Silva L, Lakhani SR. The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers. Fam Cancer. 2010:9(4):545-553. 9. Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series selected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117-1130. 10. Lu KH, Wood ME, Daniels M, et al. American Society of Clinical Oncology. American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. J Clin Oncol. 2014;32(8):833-840. 11. Society of Gynecologic Oncology. SGO clinical practice statement: genetic testing for ovarian cancer. October 2014. http://www.sgo.org/clinical-practice/guidelines/genetic-testing-for-ovarian-cancer/. 12. Meyer LA, Anderson ME, Lacour RA, et al. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol. 2010;115(5):945-952. 13. Eichmeyer JN, Burnham C, Sproat P, Tivis R, Beck TM. The value of a genetic counselor: improving identification of cancer genetic counseling patients with chart review. J Genet Couns. 2014;23(3):323-329. 14. Daniels MS, Babb SA, King RH, et al. Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study. J Clin Oncol. 2014;32(12):1249-1255. 15. Song H, Cicek MS, Dicks E, et al. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Gen. 2014;(April 30):1-7. 16. King MC, Marks JH, Mandell JB; The New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):642-646. 17. Ford J. BRCA1 and BRCA2: Clinical genomics and target for therapeutics. Presented at: 2014 ASCO Annual Meeting, June 1, 2014. Chicago, IL. 18. Geier L. BRCA mutation carriers: how to find them, what to do with them. Presented at: 2013 Community Oncology Alliance Conference; March 20-23, 2013. 19. FORCE Web site. Understanding BRCA & HBOC > Finding Specialists & Paying for Care > Insurance & Financial Issues; http://www.facingourrisk.org. Accessed November 17, 2014. 20. Pal T, Permuth-Wey J, Betts, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104(12):2807-2816. 21. Tan DSP, Rothermundt C, Thomas K, et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008;26(34):5530-5536. 22. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000;283(17):2260-2265. 23. Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer. 2012;12(9):587-598. 24. Lesnock JL, Darcy KM, Tian C, et al. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br J Cancer. 2013;108(6):1231-1237. 25. Genetic Information Non-Discrimination Act, 42 USC § 2000ff-10 (2008). 26. American Cancer Society. Can ovarian cancer be prevented? https://www.cancer.org/cancer/ovarian-cancer/causes-risks-prevention/prevention.html. Accessed April 21, 2017. 27. Koczkowska M, Zuk M, Gorczynski A, et al. Detection of somatic BRCA1/2 mutations in ovarian cancer — next-generation sequencing analysis of 100 cases. Cancer Med. 2016:5(7):1640-1646.